378 related articles for article (PubMed ID: 27146381)
1. Clinical Trial Design Issues in Systemic Sclerosis: an Update.
Gordon JK; Domsic RT
Curr Rheumatol Rep; 2016 Jun; 18(6):38. PubMed ID: 27146381
[TBL] [Abstract][Full Text] [Related]
2. Hit hard and early: analysing the effects of high-dose methylprednisolone on nailfold capillary changes and biomarkers in very early systemic sclerosis: study protocol for a 12-week randomised controlled trial.
van den Hombergh WMT; Kersten BE; Knaapen-Hans HKA; Thurlings RM; van der Kraan PM; van den Hoogen FHJ; Fransen J; Vonk MC
Trials; 2018 Aug; 19(1):449. PubMed ID: 30134971
[TBL] [Abstract][Full Text] [Related]
3. Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials.
Khanna D; Brown KK; Clements PJ; Elashoff R; Furst DE; Goldin J; Seibold JR; Silver RM; Tashkin DP; Wells AU
Clin Exp Rheumatol; 2010; 28(2 Suppl 58):S55-62. PubMed ID: 20576216
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial design in scleroderma: where are we and where do we go next?
Chung L; Denton CP; Distler O; Furst DE; Khanna D; Merkel PA;
Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S97-102. PubMed ID: 22691217
[TBL] [Abstract][Full Text] [Related]
5. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis.
White B; Bauer EA; Goldsmith LA; Hochberg MC; Katz LM; Korn JH; Lachenbruch PA; LeRoy EC; Mitrane MP; Paulus HE
Arthritis Rheum; 1995 Mar; 38(3):351-60. PubMed ID: 7880189
[TBL] [Abstract][Full Text] [Related]
6. Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment.
Affandi AJ; Radstake TR; Marut W
Semin Immunopathol; 2015 Sep; 37(5):475-87. PubMed ID: 26168983
[TBL] [Abstract][Full Text] [Related]
7. Systemic sclerosis: from pathogenesis to targeted therapy.
Denton CP
Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S3-7. PubMed ID: 26457375
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapy of systemic sclerosis.
Postlethwaite AE; Harris LJ; Raza SH; Kodura S; Akhigbe T
Expert Opin Pharmacother; 2010 Apr; 11(5):789-806. PubMed ID: 20210685
[TBL] [Abstract][Full Text] [Related]
9. Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.
Distler O; Cozzio A
Semin Immunopathol; 2016 Jan; 38(1):87-95. PubMed ID: 26577237
[TBL] [Abstract][Full Text] [Related]
10. Clinical trials in systemic sclerosis: lessons learned and outcomes.
Matucci-Cerinic M; Steen VD; Furst DE; Seibold JR
Arthritis Res Ther; 2007; 9 Suppl 2(Suppl 2):S7. PubMed ID: 17767745
[TBL] [Abstract][Full Text] [Related]
11. Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development.
Castelino FV; Varga J
Expert Rev Clin Immunol; 2013 Nov; 9(11):1077-90. PubMed ID: 24168414
[TBL] [Abstract][Full Text] [Related]
12. [B cell abnormalities and therapeutic strategies in systemic sclerosis].
Yoshizaki A
Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):197-206. PubMed ID: 27320935
[TBL] [Abstract][Full Text] [Related]
13. An update on recent randomized clinical trials in systemic sclerosis.
Boleto G; Avouac J; Allanore Y
Joint Bone Spine; 2021 Oct; 88(5):105184. PubMed ID: 33887472
[TBL] [Abstract][Full Text] [Related]
14. Innovative antifibrotic therapies in systemic sclerosis.
Beyer C; Distler O; Distler JH
Curr Opin Rheumatol; 2012 May; 24(3):274-80. PubMed ID: 22450392
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic criteria of systemic sclerosis.
Hudson M; Fritzler MJ
J Autoimmun; 2014; 48-49():38-41. PubMed ID: 24461384
[TBL] [Abstract][Full Text] [Related]
16. From mechanisms of action to therapeutic application: A review on current therapeutic approaches and future directions in systemic sclerosis.
Del Papa N; Zaccara E
Best Pract Res Clin Rheumatol; 2015 Dec; 29(6):756-69. PubMed ID: 27107511
[TBL] [Abstract][Full Text] [Related]
17. Systemic sclerosis in 2014: Advances in cohort enrichment shape future of trial design.
Allanore Y; Distler O
Nat Rev Rheumatol; 2015 Feb; 11(2):72-4. PubMed ID: 25561368
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic trials for systemic sclerosis: an update.
Sardana K; Garg VK
Indian J Dermatol Venereol Leprol; 2008; 74(5):436-46. PubMed ID: 19052400
[TBL] [Abstract][Full Text] [Related]
19. Rationally-based therapeutic disease modification in systemic sclerosis: Novel strategies.
Asano Y; Varga J
Semin Cell Dev Biol; 2020 May; 101():146-160. PubMed ID: 31859147
[TBL] [Abstract][Full Text] [Related]
20. Emerging drugs and therapeutics for systemic sclerosis.
Lee JJ; Pope JE
Expert Opin Emerg Drugs; 2016 Dec; 21(4):421-430. PubMed ID: 27813423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
